Dyzantil^® is a modified-release tablet of sodium valproate indicated for:

• Under 55: For all female and all male patients initiating valproate: Treatment of generalised, partial or other epilepsy only when there is no other effective or tolerated treatment.

• For all female patients aged over 55 years and male patients established on treatment with valproate or aged over 55 years: Treatment of generalised, partial or other epilepsy.

Available as:

200mg modified-release tablets

300mg modified-release tablets

500mg modified-release tablets

Dyzantil is bioequivalent to Epilim Chrono (sodium valproate) MR tablets (Sanofi, Reading, UK).²

Dyzantil could offer significant cost savings to your practice and integrated care board/system (ICB/S).^3*

The NHS could save 30% by prescribing Dyzantil by brand for new generic sodium valproate MR tablet prescriptions.^3*

Dyzantil is one of Aspire Pharma’s cost saving category C prolonged-release products.

In addition Dyzantil:

Has a range of strengths available;

Is available from mainline wholesalers;

Has a high level of stockholdings;

Is bioequivalent to the originator brand;²

Price guaranteed^**

*30% saving on the cost of Category C sodium valproate modified-release tablets in the England, Wales and NI Drug Tariffs.  **No change in price subject to no material change to products or Category C of the England, Wales and NI drug tariffs until the 2025 VPAG review.

References: 1) Dyzantil SmPCs. 2) Data on file, 1010506915 v 2.0 September 2022. 3) February 2024 UK Drug Tariffs.

DYZ1010506B2_FEB2024